Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
      QxMD      Google Scholar   
Citation:
Immunotherapy vol 13 (9) 727-734
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
3258  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA233180, UG1CA233253, UG1CA233247, UG1CA233339, UG1CA232760  
Corr. Author:
 
Authors:
                                     
Networks:
CORA, FL023, FL065, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC010, NE003   
Study
Alliance-A081801
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
NSCLC, adjuvant chemotherapy, lung adenocarcinoma, lung squamous cell carcinoma, pembrolizumab